Inventiva (Euronext Paris and NASDAQ: IVA) has appointed three new members to its leadership team, including Axel-Sven Malkomes as chief financial officer, Susan Coles as chief legal officer, and Pamela Herbster as chief people officer.
According to Inventiva, the appointments strengthen its leadership team ahead of the expected top-line data readout from its NATiV3 Phase 3 trial evaluating lanifibranor in adult patients with metabolic dysfunction-associated steatohepatitis (MASH), expected in the fourth quarter of 2026.
Mr. Malkomes brings more than 30 years of investment banking, corporate leadership, and private equity across life sciences and healthcare. He was most recently chief financial officer at CureVac, now BioNTech (NASDAQ: BNTX). Ms. Coles recently served as head of legal and finance at closely held Vivet Therapeutics and brings extensive experience across both public and private life science companies. Ms. Herbster comes to Inventiva from Sage Therapeutics, now a subsidiary of Supernus Pharmaceuticals (NASDAQ: SUPN), where she led both human resources and business operations.
In a statement, Andrew Obenshain, CEO of Inventiva, commented, “I am delighted to welcome Axel-Sven, Susan and Pamela to the leadership team. The anticipated Phase 3 top-line readout for lanifibranor in Q4 2026 marks a defining moment for Inventiva. With this strengthened leadership team, bringing complementary expertise across strategy, finance, legal, and people, we believe we are well-positioned to guide Inventiva through its next phase with confidence, discipline, and speed, from pivotal data readouts to potential regulatory submissions and commercialization.”
